General description
INN
Nivolumab
ATC codes
Medicine type
Biological agent
EML status history
First added in 2019
(TRS
1021)
for
Melanoma of skin
Application rejected in 2019
(TRS
1021)
for
Other specified malignant neoplasms of bronchus or lung
Added in 2025
(TRS
1064)
for
Melanoma of skin
Application rejected in 2025
(TRS
1064)
for
Renal cell carcinoma of kidney, except renal pelvis
Application rejected in 2025
(TRS
1064)
for
Squamous cell carcinoma of oesophagus
Application rejected in 2025
(TRS
1064)
for
Adenocarcinoma of oesophagogastric junction
Application rejected in 2025
(TRS
1064)
for
Adenocarcinoma of stomach
Therapeutic equivalent for
Wikipedia
DrugBank
Recommendations
Section
Immunomodulators
- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion